CSIMarket
 
Viridian Therapeutics Inc   (VRDN)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $17.3400 $0.25 1.463%
Day's High: $17.62 Week Perf: -1.48 %
Day's Low: $ 16.16 30 Day Perf: -9.83 %
Volume (M): 1,536 52 Wk High: $ 30.30
Volume (M$): $ 26,636 52 Wk Avg: $20.29
Open: $16.95 52 Wk Low: $10.93



 Market Capitalization (Millions $) 776
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -238
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 1

Viridian Therapeutics Inc
Viridian Therapeutics Inc is a biotechnology company that focuses on developing treatments for metabolic diseases. The company is known for its expertise in gene therapy and its innovative approach to developing personalized medicines. Viridian Therapeutics aims to address various metabolic diseases, such as obesity and type 2 diabetes, by targeting specific genetic factors and developing targeted therapies. The company takes advantage of advances in genomic research to identify genetic mutations and develop treatments that directly address the underlying causes of metabolic diseases. With a strong emphasis on personalized medicine, Viridian Therapeutics aims to revolutionize the way metabolic diseases are treated by providing tailored therapies that are specifically designed for each patient.


   Company Address: 221 Crescent Street, Suite 401 Waltham 2453 MA
   Company Phone Number: 272-4600   Stock Exchange / Ticker: NASDAQ VRDN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Viridian Therapeutics Inc

Viridian Therapeutics Inc Shows Resilience in the Face of Market Challenges, Despite Increased Losses

The stock market has been a topic of interest for many investors and traders alike, and despite the weak demand seen in the Dec 31 2023 report, there are some promising aspects to discuss. One company that has caught the attention of many is Viridian Therapeutics Inc (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases.
In the recent report, Viridian Therapeutics Inc showcased their determination and resilience, as they navigated through challenging market conditions. Although the company's net loss per share inched up to $-1.12 from $-0.72, it is noteworthy to mention that they have made significant progress compared to the previous fiscal year. Viridian Therapeutics Inc managed to increase their revenue from $0.07 million to $0.11 million, despite a 31.429% drop. This steady revenue stream is a positive signal for investors.

Stock Issue News

Advancing Breakthrough Biotechnology Innovations: Viridian Therapeutics Revolutionizes Treatment Landscape for Rare Diseases

Published Wed, Jan 17 2024 9:01 PM UTC



WALTHAM, Mass. - In a significant move towards revolutionizing medical advancements for serious and rare diseases, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company, has announced the commencement of an underwritten public offering of shares of its common stock and Series B preferred stock. This offering signifies Viridian's commitment to discover...

Business Update

Viridian Therapeutics Shares 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Published Mon, Jan 8 2024 1:00 PM UTC

Recently, Viridian Therapeutics, a leading biotechnology company dedicated to the development of innovative medicines for serious and rare diseases, announced their participation in the prestigious 42nd Annual J.P. Morgan Healthcare Conference. The event, held in San Francisco, California, serves as a platform for industry leaders to showcase their progress and discuss futur...

Product Service News

A New Frontier in Thyroid Eye Disease Therapy: Viridian Therapeutics Unveils Groundbreaking Clinical Data and Drugs with Extended Half-Life

Published Mon, Dec 18 2023 12:00 PM UTC


Viridian Therapeutics Inc., a pioneering biotech corporation with a focus on the development of innovative medicines for severe and rare illnesses, has announced VRDN-003 as their leading subcutaneous (SC) program for thyroid eye disease (TED) after achieving promising clinical data from a Phase 1 investigation in healthy subjects. This landmark announcement represents ...

Viridian Therapeutics Inc

Alarming and Rapid Decline Plagues the Company in Q3 2023: A Deep Dive into the Troubles at XYZ Corporation



Viridian Therapeutics Inc, a biotechnology company that specializes in developing groundbreaking treatments for serious and rare diseases, recently released its financial results for the third quarter of 2023. Unfortunately, the figures were far from inspiring, revealing a significant decline in revenue and a widening net loss. This article will analyze the impact of these results on the company's future prospects and explore potential challenges that lie ahead.
1. Revenue Decline and Net Loss:
During the July to September 2023 period, Viridian Therapeutics experienced a disastrous decline in revenue, plummeting by -93.975% to just $0.07 million. Such a drastic reduction is a cause for concern, as it suggests a lack of market demand or potential issues with the company's products. Additionally, net loss per share increased to $-1.09, further signaling financial distress.






 

Viridian Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Viridian Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Viridian Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com